Skip to content

Posts by Former NIMH Director Thomas Insel about Medications

Ketamine

By Thomas Insel on

Ongoing research is investigating the long-term efficacy and safety of the anesthetic drug ketamine, which studies have shown can rapidly lift depressive symptoms; Dr. Insel talks about the status of ketamine in his blog.

Read More

Antipsychotics: Taking the Long View

By Thomas Insel on

Antipsychotics help people through the crisis of acute psychosis, but the long-term management of chronic mental illness is another matter. It appears that what we currently call “schizophrenia” may comprise disorders with quite different trajectories. For some people, remaining on medication long-term might impede a full return to wellness. For others, discontinuing medication can be disastrous.

Read More

Experimental Medicine

By Thomas Insel on

Dr. Insel discusses the crisis of medication development for mental disorders.

Read More

Balancing Immediate Needs with Future Innovation

By Thomas Insel on

Dr. Insel responds to discussion from the National Advisory Mental Health Council concerning the need to balance research funding for basic science and mental health services.

Read More

Treatment Development: Where do we go from here?

By Thomas Insel on

Dr. Insel discusses opportunities for treatment development.

Read More

NIMH’s Top 10 Research Advances of 2011

By Thomas Insel on

Dr. Insel shares NIMH’s Top 10 Research Advances for 2011.

Read More

Treatment Development: Where do we go from here?

By Thomas Insel on

Dr. Insel discusses opportunities for treatment development.

Read More

Treatment Development: The Past 50 Years

By Thomas Insel on

Dr. Insel discusses the state of psychiatric research and development (R&D) in the public and private sectors

Read More

Antidepressants: A complicated picture

By Thomas Insel on

Dr. Insel discusses the complicated nature of research on the efficacy antidepressants.

Read More

NIMH’s Top 10 Research Events and Advances of 2010

By Thomas Insel on

10 breakthroughs and events of 2010 which are changing the way we approach mental disorders.

Read More

Wanted: A Few Good Assays

By Thomas Insel on

NIMH/NIH is nurturing medications development via assays that probe new molecular targets relevant to mental disorders.

Read More